Name: Why the stated $1bn market opportunity in only three cancer types could be the tip of the iceberg.
Uploaded: 2024-01-17T07:28:03.730261+00:00
Duration: 432 s
Channel: Vox Markets
Description: Why the stated $1bn market opportunity in only three cancer types could be the tip of the iceberg.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/006/915/006915/video_pMVDRMz.mp4#t=302

Vox Markets

Why the stated $1bn market opportunity in only three cancer types could be the tip of the iceberg.

How the latest in vivo trial results strengthens and facilitates the extension of patent applications for POLB 001 in cancer immunotherapy-induced CRS

The significance of the potential for POLB 001 to be delivered as an oral therapy to allow use in an outpatient setting

How an Independent Advisory Board is supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS.

Vox Markets talks to Poolbeg Pharma CEO Jeremy Skillington and Chief Business Office David Allman about the latest positive results for its lead asset POLB 001 which could help it tap into what could be a $1bn market opportunity in cancer immunotherapy.

0:30 How the latest in vivo trial results strengthens and facilitates the extension of patent applications for POLB 001 in cancer immunotherapy-induced CRS
1:36 The significance of the potential for POLB 001 to be delivered as an oral therapy to allow use in an outpatient setting
3:12 How an Independent Advisory Board is supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS.
5:02 Why the stated $1bn market opportunity in only three cancer types could be the tip of the iceberg

Vox Markets talks to Poolbeg Pharma CEO Jeremy Skillington and Chief Business Office David Allman about the latest positive results for its lead asset POLB 001 which could help it tap into what could be a $1bn market opportunity in cancer immunotherapy.0:30 How the latest in vivo trial results strengthens and facilitates the extension of patent applications for POLB 001 in cancer immunotherapy-induced CRS 1:36 The significance of the potential for POLB 001 to be delivered as an oral therapy to allow use in an outpatient setting 3:12 How an Independent Advisory Board is supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS. 5:02 Why the stated $1bn market opportunity in only three cancer types could be the tip of the iceberg

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/006/915/006915/video_pMVDRMz.mp4